Literature DB >> 24215362

Zinc finger protein in severe dry eye syndrome.

Seung Hoon Lee1, Min-Yi Park, Kyoung Woo Kim, Sung Wook Wee, Jae Chan Kim.   

Abstract

PURPOSE: Zinc finger protein known to induce squamous metaplasia and regulate vitamin A expression has been few investigated as tear protein. We investigated tear protein variations in patients with dry eye syndrome (DES).
MATERIALS AND METHODS: Tears from healthy subjects as control and patients with DES were collected. Tear proteins were separated by one-dimensional electrophoresis. The protein bands were analyzed by nano liquid chromatography-mass spectrometry.
RESULTS: Compared to the controls, significant down-regulation of lactoferrin and lysozyme was detected, while significant up-regulation was observed for serum albumin in patients with DES. DES grade 4 patients showed different protein patterns. Zinc-finger motif-enhancer binding-protein-1 gamma and bromodomain adjacent to zinc finger domain 2B were detected in DES grade 4 patients.
CONCLUSIONS: Tear protein changes are valuable to diagnosis DES. Zinc finger proteins may be associated with pathophysiology of severe DES. Further studies are needed to better understand the relationship of zinc finger proteins in tear of patients with DES.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24215362     DOI: 10.3109/02713683.2013.851705

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  2 in total

Review 1.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

2.  Lactoferrin Concentration in Human Tears and Ocular Diseases: A Meta-Analysis.

Authors:  Erika Ponzini; Lorenza Scotti; Rita Grandori; Silvia Tavazzi; Antonella Zambon
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-10-01       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.